📈 Jumpstart Signal Watchlist — August 28, 2026

🏢 What they do: Mitek Systems, Inc. (MITK) specializes in digital identity verification, authentication, biometrics, mobile image capture, and fraud detection solutions. Its enterprise-grade platform enables secure onboarding, check deposits, transaction protection, and real-time defense against threats like deepfakes and synthetic fraud for banks, fintechs, and other organizations.
- 🎯 Current $18.85 is 6% below 3yr high $20.14 · ⏳ SMA200 $14.03 (current price $18.85 is above) · 💰 Market Cap $850M
- MITK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 240% (>20%); Revenue growth 18% (>15%); Low LT D/E 0.20 (<1.0); PEG ratio 0.17 (<1.5).
⏰ Entry (E): 4/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 55 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Mitek Reports Fiscal Third Quarter Revenue of $54.0 Million, Up 18% Year-Over-Year; Raises Full-Year Outlook — Business Wire.
🤖 Mitek named Aaron Seyler as Chief Revenue Officer, a leadership move that can support go-to-market execution and revenue growth. The article also appears alongside the company’s Q3 results and raised outlook, reinforcing a constructive near-term setup for MITK.
🤖 Mitek reported Q3 revenue of $54.0 million, raised full-year fiscal 2026 revenue guidance to $195 million-$200 million, and lifted its adjusted EBITDA margin outlook. The company also highlighted record Fraud & Identity SaaS revenue, which is supportive for the stock.
✅ Mitek Systems Inc (MITK) (Q3 2026) Earnings Call Highlights — Yahoo Finance.
🤖 The earnings call highlights show Mitek beat expectations on both earnings and revenue and paired the results with raised full-year guidance. Better-than-expected operating performance and improved outlook are typically bullish for the shares.
✅ Mitek Systems (MITK) Q3 Earnings and Revenues Beat Estimates — Yahoo Finance.
🤖 Mitek posted adjusted EPS of $0.34 versus expectations of $0.26 and revenue of $54.04 million, also above estimates. Beating consensus on both lines generally supports the stock, especially when accompanied by guidance increases.
🍭 Bonus (B): 10/10 — Computer Peripheral Equipment (Technology sector)

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $12.89 is 9% below 3yr high $14.14 · ⏳ SMA200 $6.40 (current price $12.89 is above) · 💰 Market Cap $728M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (21.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Paysign (NASDAQ:PAYS) Hits New 12-Month High — MarketBeat.
🤖 The article says Paysign reached a new 12-month high and highlights multiple bullish analyst actions, including higher price targets and Buy ratings. That combination is supportive for the stock because it reinforces momentum and improving sentiment.
✅ Paysign (NASDAQ:PAYS) Posts Quarterly Earnings ... — MarketBeat.
🤖 The article highlights Paysign's better-than-expected quarterly results and mentions a raised full-year 2026 outlook. Strong earnings and improved guidance are typically positive for the stock.
⚪️ Paysign (NASDAQ:PAYS) Shares Down 5.3% — MarketBeat.
🤖 This piece focuses on a daily pullback in the share price rather than any company-specific deterioration. The article still notes that analysts remain broadly positive with a Buy consensus and a $13.33 target, which offsets the weak price action.
⚪️ Paysign (NASDAQ:PAYS) Stock Rating Lowered by Wall Street Zen — MarketBeat.
🤖 The downgrade from strong-buy to buy is only a modest negative because the broader analyst view remains Buy. The article shows mixed signals rather than a clear bearish shift.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: The Manitowoc Company is a global manufacturer of engineered lifting solutions, mainly cranes and related equipment. Its products include mobile hydraulic cranes, tower cranes, crawler cranes, boom trucks, and associated aftermarket services and support.
- 🎯 Current $19.59 is 6% below 3yr high $20.87 · ⏳ SMA200 $13.41 (current price $19.59 is above) · 💰 Market Cap $706M
- MTW shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 875% (>20%); Low LT D/E 0.66 (<1.0); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (7.1%)
- 🔔 Strong above EMA50 (20.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Manitowoc at 17th Annual Midwest IDEAS Conference — Investing.com.
🤖 Manitowoc discussed its shift toward higher-margin services and aftermarket revenue, along with strong order momentum and a backlog above $1 billion. The article frames the company’s strategy and operating trends as constructive for the stock.
✅ Manitowoc Q2 2026 slides: orders surge 56%, guidance raised on ... — Investing.com.
🤖 The article highlights a major earnings beat, strong order growth, and higher full-year guidance, all of which support a positive read-through for MTW. The sharp post-earnings stock move also signals a favorable market reaction.
⚪️ The Manitowoc Company to Present and Host 1x1 Meetings at the Midwest IDEAS Investor Conference — Business Wire.
🤖 This is a conference participation announcement with no new financial results, guidance, or analyst opinion. It does not appear to change MTW’s fundamentals or outlook.
🍭 Bonus (B): 0/10 — Construction Machinery

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $10.83 is 17% below 3yr high $13.11 · ⏳ SMA200 $8.35 (current price $10.83 is above) · 💰 Market Cap $1.8B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (10.0%)
- 🔔 Strong above EMA50 (13.4%)
- 🔔 EMA bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results — Business Wire.
🤖 Vir reported a major revenue and earnings beat, plus it highlighted strong Phase 2 SOLSTICE data and progress across its hepatitis delta and oncology pipelines. The company also said its cash position rose to about $1.01 billion, which supports execution and lowers near-term financing risk.
✅ Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Highlights — Yahoo Finance.
🤖 This summary emphasizes the same upbeat quarterly update, including strong clinical data, completed enrollment in registrational trials, and a much stronger cash balance. Those catalysts are constructive for the stock because they improve both the pipeline outlook and financial durability.
✅ Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS — MarketBeat.
🤖 The article focuses on Vir's earnings beat and revenue well above expectations, along with encouraging pipeline updates. Better-than-expected financial results and continued clinical progress are generally supportive for the share price.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Methode Electronics designs, engineers, and manufactures custom mechatronic and electronic components and systems. Its products include user interfaces, LED lighting, sensors, power distribution products, and related solutions for automotive, industrial, appliance, aerospace, and other markets.
- 🎯 Current $18.21 is 44% below 3yr high $32.58 · ⏳ SMA200 $9.93 (current price $18.21 is above) · 💰 Market Cap $694M
- MEI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 36/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 101% (>20%); Revenue growth 16% (>15%); Low LT D/E 0.48 (<1.0).
⏰ Entry (E): 7/20
- 🔔 Strong above EMA21 (13.1%)
- 🔔 Strong above EMA50 (20.1%)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Methode Electronics (NYSE:MEI) Shares Up 7.3% — MarketBeat.
🤖 The article says shares rose 7.3% and highlights a new consensus Hold rating with a higher average target price of $22.00. It also notes recent mixed analyst views, but the price action and upbeat target revision are constructive for the stock.
✅ Why Methode Electronics (MEI) Stock Is Trading Up Today — Yahoo Finance.
🤖 The stock jumped after Craig-Hallum initiated coverage with a Buy rating and a $30 target. The piece frames recent operational improvements and a cyclical rebound as potential turnaround catalysts, which is supportive for MEI.
⚪️ Methode Electronics (NYSE:MEI) Raised to "Hold" at Zacks Research — MarketBeat.
🤖 Zacks moved the stock from Strong Sell to Hold, which is an improvement but not a strong bullish call. The article also repeats the recent earnings miss despite revenue beating estimates, making the overall impact mixed.
🍭 Bonus (B): 0/10 — Electronic Connectors

🏢 What they do: HealthStream provides software and online services for healthcare organizations to manage workforce learning, training, credentialing, competency, and scheduling. Its tools help hospitals and other care providers develop staff and support compliance and performance management.
- 🎯 Current $29.38 is 14% below 3yr high $34.07 · ⏳ SMA200 $23.97 (current price $29.38 is above) · 💰 Market Cap $859M
- HSTM shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (11.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 28% (>20%); Low LT D/E 0.08 (<1.0); PEG ratio 1.47 (<1.5).
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ HealthStream Announces Second Quarter 2026 Results — Business Wire.
🤖 HealthStream reported record quarterly revenue of $83.7 million, up 12.5% year over year, with EPS of $0.23 and adjusted EBITDA of $20.6 million. The company also reiterated a positive capital return policy by declaring a $0.035 quarterly dividend.
✅ HealthStream outlines $327M-$332M 2026 revenue outlook while expanding career networks investment — Seeking Alpha.
🤖 The article highlights strong Q2 results and notes that management raised its full-year 2026 revenue outlook to $327 million-$332 million. It also says the company is investing more in career networks and platform development, which supports the growth narrative.
⚪️ HealthStream (NASDAQ:HSTM) Downgraded by Wall Street Zen to Hold — MarketBeat.
🤖 The downgrade from Buy to Hold is a modest negative signal, but it does not indicate a major deterioration in fundamentals. Because the stock already had a consensus Hold rating, the impact appears limited.
🍭 Bonus (B): 10/10 — Computer Programming & Data Processing (Technology sector)

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $34.26 is 4% below 3yr high $35.53 · ⏳ SMA200 $24.75 (current price $34.26 is above) · 💰 Market Cap $4.4B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (12.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance — Business Wire.
🤖 Concentra reported strong Q2 2026 results, including 10.0% revenue growth and 22.5% Adjusted EBITDA growth, while also raising full-year 2026 guidance. The company additionally declared a cash dividend and outlined a planned leadership transition, all of which support a positive stock view.
✅ Truist Financial Raises Concentra Group Holdings Parent Price Target to 42.00 — MarketBeat.
🤖 Truist lifted its price target and maintained a buy rating, signaling improved analyst confidence in CON. Higher targets from analysts typically support sentiment and can be constructive for the stock.
⚪️ Concentra appoints Matt DiCanio as CEO in planned leadership transition — Seeking Alpha.
🤖 This article covers a planned management succession, with Matt DiCanio set to become CEO on Nov. 1, 2026 and Keith Newton moving to executive chairman. The transition is strategically important, but it is not directly a financial operating update, so the stock impact is neutral.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: HF Sinclair Corporation (DINO) is an independent energy company that operates refineries across the mid-continent, Southwest, Rocky Mountain regions, and Pacific Northwest in the United States, producing and marketing gasoline, diesel fuel, jet fuel, renewable diesel, specialty lubricants, chemicals, and asphalt.
- 🎯 At/above 3yr high $99.71 (current $99.71) · ⏳ SMA200 $64.07 (current price $99.71 is above) · 💰 Market Cap $22.3B
- DINO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (13.4% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 348% (>20%); Revenue growth 53% (>15%); ROE 19% (>15%).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (7.9%)
- 🔔 Strong above EMA50 (16.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ HF Sinclair (DINO) Hits New 12-Month High — MarketBeat.
🤖 The article highlights a new 52-week high, a dividend increase, and a strong quarterly beat on earnings and revenue. Those details are favorable for DINO because they suggest improving fundamentals and sustained investor demand.
✅ BlackRock Inc. Makes New $1.29 Billion Investment in HF Sinclair Corporation $DINO — MarketBeat.
🤖 This item reports a large new institutional stake in HF Sinclair, alongside reference to strong quarterly results and a higher dividend. A major purchase by a large asset manager can be interpreted as a vote of confidence in the stock.
✅ Foster & Motley Inc. Purchases New Stake in HF Sinclair Corporation $DINO — MarketBeat.
🤖 The article says Foster & Motley initiated a new position and reiterates HF Sinclair’s earnings beat and dividend hike. New institutional buying and upbeat operating results are constructive for the shares.
🍭 Bonus (B): 0/10 — Pipelines (Except Natural Gas)

🏢 What they do: American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns, and operates a diversified portfolio of clinical healthcare properties, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, the United Kingdom, and the Isle of Man.
- 🎯 Current $55.53 is 4% below 3yr high $57.72 · ⏳ SMA200 $50.53 (current price $55.53 is above) · 💰 Market Cap $10.8B
- AHR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (14.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 167% (>20%); Revenue growth 27% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 51 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ KeyBanc raises American Healthcare REIT price target on pipeline — Investing.com.
🤖 KeyBanc lifted its price target to $68 from $58 while keeping an Overweight rating, implying meaningful upside. The note is bullish because it signals analyst confidence in AHR’s growth pipeline and valuation.
✅ American Healthcare REIT, Inc. (NYSE:AHR) Receives Average Recommendation of "Moderate Buy" from Analysts — MarketBeat.
🤖 The article says AHR retains a Moderate Buy consensus from 14 analysts, with an average target above the market price. That combination of broad analyst support and upside price targets is favorable for the stock.
✅ American Healthcare REIT (NYSE:AHR) Price Target Raised to $61.00 at Royal Bank Of Canada — MarketBeat.
🤖 Royal Bank of Canada raised its target to $61 from $56 and maintained an Outperform rating. The higher target and positive rating suggest continued analyst optimism about AHR's shares.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: ScanSource is a technology distributor that connects hardware, software, connectivity, and cloud solutions to channel partners and businesses. Its products and services include point-of-sale systems, barcode and data-capture equipment, networking, communications, physical security, payments, and related value-added services.
- 🎯 Current $56.55 is 4% below 3yr high $58.89 · ⏳ SMA200 $43.66 (current price $56.55 is above) · 💰 Market Cap $1.1B
- SCSC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 40% (>20%); Revenue growth 17% (>15%); Low LT D/E 0.38 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ ScanSource shares jump 19% after Q4 beat and $220.5 ... — Yahoo Finance.
🤖 ScanSource reported stronger-than-expected fourth-quarter results and announced a $220.5 million cash acquisition of MicroAge. The earnings beat, revenue strength, and growth-through-acquisition strategy are constructive for the stock.
✅ ScanSource (NASDAQ:SCSC) Upgraded to "Buy" at Wall Street Zen — MarketBeat.
🤖 Wall Street Zen upgraded ScanSource to Buy, adding to generally mixed but improving analyst sentiment. The same coverage also highlighted the company’s earnings beat, which supports a favorable near-term outlook.
✅ ScanSource, Inc. $SCSC Shares Sold by Denali Advisors LLC — MarketBeat.
🤖 This article centers on ScanSource’s strong quarterly results, including EPS and revenue well above expectations. It also notes multiple analyst changes around the stock, but the dominant takeaway is the positive earnings surprise.
🍭 Bonus (B): 0/10 — Computers & Software - Wholesale